Compare CLVT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLVT | HROW |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2008 |
| Metric | CLVT | HROW |
|---|---|---|
| Price | $2.20 | $29.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $3.01 | ★ $62.25 |
| AVG Volume (30 Days) | ★ 4.0M | 617.3K |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 68.75 | ★ 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $974,345,000.00 | N/A |
| Revenue This Year | N/A | $28.13 |
| Revenue Next Year | N/A | $56.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.61 | N/A |
| 52 Week Low | $1.42 | $25.76 |
| 52 Week High | $3.87 | $54.98 |
| Indicator | CLVT | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 60.75 | 49.41 |
| Support Level | $1.83 | $28.54 |
| Resistance Level | $2.38 | $30.28 |
| Average True Range (ATR) | 0.19 | 1.80 |
| MACD | 0.02 | 0.32 |
| Stochastic Oscillator | 71.51 | 42.17 |
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.